Selected research
Industry Research
Radiolabeled Compounds Synthesis Service Industry Research Report 2026
Market perspective
The global Radiolabeled Compounds Synthesis Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Radiolabeled Compounds Synthesis Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Radiolabeled Compounds Synthesis Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Radiolabeled Compounds Synthesis Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Radiolabeled Compounds Synthesis Service include Eurofins, Revvity, Selcia, Labcorp, Pharmaron, WuXi AppTec, AM Chemicals, SEKISUI MEDICAL CO., LTD. and Nuvisan, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Radiolabeled Compounds Synthesis Service market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Radiolabeled Compounds Synthesis Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Radiolabeled Compounds Synthesis Service Market by Company
Eurofins
Revvity
Selcia
Labcorp
Pharmaron
WuXi AppTec
AM Chemicals
SEKISUI MEDICAL CO., LTD.
Nuvisan
Almac
Novandi Chemistry
Alfa Cytology
Institute of Isotopes Co. Ltd.
Headway
ViTrax
Radiolabeled Compounds Synthesis Service Segment by Type
Carbon-14 Radiosynthesis Services
Hydrogen-3 Radiosynthesis Services
Chiral Separation and Salt Formation
Others
Radiolabeled Compounds Synthesis Service Segment by Application
Medical Diagnosis and Treatment
Material Science
Nuclear Energy
Others
Radiolabeled Compounds Synthesis Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiolabeled Compounds Synthesis Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiolabeled Compounds Synthesis Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiolabeled Compounds Synthesis Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Radiolabeled Compounds Synthesis Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Carbon-14 Radiosynthesis Services
- Hydrogen-3 Radiosynthesis Services
- Chiral Separation and Salt Formation
- Others
Applications
- Medical Diagnosis and Treatment
- Material Science
- Nuclear Energy
- Others
Companies covered
- Eurofins
- Revvity
- Selcia
- Labcorp
- Pharmaron
- WuXi AppTec
- AM Chemicals
- SEKISUI MEDICAL CO., LTD.
- Nuvisan
- Almac
- Novandi Chemistry
- Alfa Cytology
- Institute of Isotopes Co. Ltd.
- Headway
- ViTrax
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Radiolabeled Compounds Synthesis Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Carbon-14 Radiosynthesis Services
- 2.2.3 Hydrogen-3 Radiosynthesis Services
- 2.2.4 Chiral Separation and Salt Formation
- 2.2.5 Others
- 2.3 Radiolabeled Compounds Synthesis Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Medical Diagnosis and Treatment
- 2.3.3 Material Science
- 2.3.4 Nuclear Energy
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Radiolabeled Compounds Synthesis Service Breakdown Data by Type
- 3.1 Global Radiolabeled Compounds Synthesis Service Historic Market Size by Type (2021-2026)
- 3.2 Global Radiolabeled Compounds Synthesis Service Forecasted Market Size by Type (2027-2032)
4 Radiolabeled Compounds Synthesis Service Breakdown Data by Application
- 4.1 Global Radiolabeled Compounds Synthesis Service Historic Market Size by Application (2021-2026)
- 4.2 Global Radiolabeled Compounds Synthesis Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Radiolabeled Compounds Synthesis Service Market Perspective (2021-2032)
- 5.2 Global Radiolabeled Compounds Synthesis Service Growth Trends by Region
- 5.2.1 Global Radiolabeled Compounds Synthesis Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Radiolabeled Compounds Synthesis Service Historic Market Size by Region (2021-2026)
- 5.2.3 Radiolabeled Compounds Synthesis Service Forecasted Market Size by Region (2027-2032)
- 5.3 Radiolabeled Compounds Synthesis Service Market Dynamics
- 5.3.1 Radiolabeled Compounds Synthesis Service Industry Trends
- 5.3.2 Radiolabeled Compounds Synthesis Service Market Drivers
- 5.3.3 Radiolabeled Compounds Synthesis Service Market Challenges
- 5.3.4 Radiolabeled Compounds Synthesis Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Radiolabeled Compounds Synthesis Service Players by Revenue
- 6.1.1 Global Top Radiolabeled Compounds Synthesis Service Players by Revenue (2021-2026)
- 6.1.2 Global Radiolabeled Compounds Synthesis Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Radiolabeled Compounds Synthesis Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Radiolabeled Compounds Synthesis Service Head Office and Area Served
- 6.4 Global Radiolabeled Compounds Synthesis Service Players, Product Type & Application
- 6.5 Global Radiolabeled Compounds Synthesis Service Manufacturers Established Date
- 6.6 Global Radiolabeled Compounds Synthesis Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Radiolabeled Compounds Synthesis Service Market Size (2021-2032)
- 7.2 North America Radiolabeled Compounds Synthesis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Radiolabeled Compounds Synthesis Service Market Size by Country (2021-2026)
- 7.4 North America Radiolabeled Compounds Synthesis Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Radiolabeled Compounds Synthesis Service Market Size (2021-2032)
- 8.2 Europe Radiolabeled Compounds Synthesis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Radiolabeled Compounds Synthesis Service Market Size by Country (2021-2026)
- 8.4 Europe Radiolabeled Compounds Synthesis Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Radiolabeled Compounds Synthesis Service Market Size (2021-2032)
- 9.2 Asia-Pacific Radiolabeled Compounds Synthesis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Radiolabeled Compounds Synthesis Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Radiolabeled Compounds Synthesis Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Radiolabeled Compounds Synthesis Service Market Size (2021-2032)
- 10.2 South America Radiolabeled Compounds Synthesis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Radiolabeled Compounds Synthesis Service Market Size by Country (2021-2026)
- 10.4 South America Radiolabeled Compounds Synthesis Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Radiolabeled Compounds Synthesis Service Market Size (2021-2032)
- 11.2 Middle East & Africa Radiolabeled Compounds Synthesis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Radiolabeled Compounds Synthesis Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Radiolabeled Compounds Synthesis Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eurofins
- 12.1.1 Eurofins Company Information
- 12.1.2 Eurofins Business Overview
- 12.1.3 Eurofins Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.1.4 Eurofins Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.1.5 Eurofins Recent Developments
- 12.2 Revvity
- 12.2.1 Revvity Company Information
- 12.2.2 Revvity Business Overview
- 12.2.3 Revvity Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.2.4 Revvity Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.2.5 Revvity Recent Developments
- 12.3 Selcia
- 12.3.1 Selcia Company Information
- 12.3.2 Selcia Business Overview
- 12.3.3 Selcia Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.3.4 Selcia Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.3.5 Selcia Recent Developments
- 12.4 Labcorp
- 12.4.1 Labcorp Company Information
- 12.4.2 Labcorp Business Overview
- 12.4.3 Labcorp Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.4.4 Labcorp Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.4.5 Labcorp Recent Developments
- 12.5 Pharmaron
- 12.5.1 Pharmaron Company Information
- 12.5.2 Pharmaron Business Overview
- 12.5.3 Pharmaron Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.5.4 Pharmaron Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.5.5 Pharmaron Recent Developments
- 12.6 WuXi AppTec
- 12.6.1 WuXi AppTec Company Information
- 12.6.2 WuXi AppTec Business Overview
- 12.6.3 WuXi AppTec Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.6.4 WuXi AppTec Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.6.5 WuXi AppTec Recent Developments
- 12.7 AM Chemicals
- 12.7.1 AM Chemicals Company Information
- 12.7.2 AM Chemicals Business Overview
- 12.7.3 AM Chemicals Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.7.4 AM Chemicals Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.7.5 AM Chemicals Recent Developments
- 12.8 SEKISUI MEDICAL CO., LTD.
- 12.8.1 SEKISUI MEDICAL CO., LTD. Company Information
- 12.8.2 SEKISUI MEDICAL CO., LTD. Business Overview
- 12.8.3 SEKISUI MEDICAL CO., LTD. Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.8.4 SEKISUI MEDICAL CO., LTD. Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.8.5 SEKISUI MEDICAL CO., LTD. Recent Developments
- 12.9 Nuvisan
- 12.9.1 Nuvisan Company Information
- 12.9.2 Nuvisan Business Overview
- 12.9.3 Nuvisan Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.9.4 Nuvisan Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.9.5 Nuvisan Recent Developments
- 12.10 Almac
- 12.10.1 Almac Company Information
- 12.10.2 Almac Business Overview
- 12.10.3 Almac Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.10.4 Almac Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.10.5 Almac Recent Developments
- 12.11 Novandi Chemistry
- 12.11.1 Novandi Chemistry Company Information
- 12.11.2 Novandi Chemistry Business Overview
- 12.11.3 Novandi Chemistry Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.11.4 Novandi Chemistry Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.11.5 Novandi Chemistry Recent Developments
- 12.12 Alfa Cytology
- 12.12.1 Alfa Cytology Company Information
- 12.12.2 Alfa Cytology Business Overview
- 12.12.3 Alfa Cytology Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.12.4 Alfa Cytology Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.12.5 Alfa Cytology Recent Developments
- 12.13 Institute of Isotopes Co. Ltd.
- 12.13.1 Institute of Isotopes Co. Ltd. Company Information
- 12.13.2 Institute of Isotopes Co. Ltd. Business Overview
- 12.13.3 Institute of Isotopes Co. Ltd. Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.13.4 Institute of Isotopes Co. Ltd. Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.13.5 Institute of Isotopes Co. Ltd. Recent Developments
- 12.14 Headway
- 12.14.1 Headway Company Information
- 12.14.2 Headway Business Overview
- 12.14.3 Headway Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.14.4 Headway Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.14.5 Headway Recent Developments
- 12.15 ViTrax
- 12.15.1 ViTrax Company Information
- 12.15.2 ViTrax Business Overview
- 12.15.3 ViTrax Revenue in Radiolabeled Compounds Synthesis Service Business (2021-2026)
- 12.15.4 ViTrax Radiolabeled Compounds Synthesis Service Product Portfolio
- 12.15.5 ViTrax Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst